B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia

Table 1

Overview of BAFF receptors.

	Gene	Forms	Ligands	Affinity to BAFF ()	Tissue expression	Function	Clinical relevance
BAFF-R; (BAFF-receptor, TNFRSF13C, BLyS, BR3, CD268) [13]	22q13.2; 3 exons [13]	Membrane bound, soluble (produced by decidual cells) [8, 14]	BAFF [8]	16 nmol·l^−1 [8]	B-, T-cells [15, 16]; mature and immature adipose tissue [17]	B-cell proliferation [18],; T-cell proliferation [16]	BAFF-R is constitutively saturated in autoimmune and lymphoproliferative diseases [15, 19, 20]
TACI; (transmembrane activator and calcium signal-modulating cyclophilin ligand, TNFRSF13B, CD267) [21]	17p11.2; 5 exons [21]	Membrane bound [8]	BAFF, APRIL [8]	146 nmol·l^−1[22]	B-, T-cells; immature adipose tissue [17]	T-cell activation [23] and humoral immunity response modulation [24, 25]	Mutations may result in common variable immunodeficiency [26, 27]
BCMA; (B-cell maturation antigen, TNFRSF17) [28]	16p13.1; 3 exons [28]	Membrane bound [8]	APRIL (BAFF) [8]	1600 nmol·l^−1 [8]	B-cells; immature [17]	Long-term plasma cell survival, B-cell antigen presentation [29]	Protection of multiple myeloma cells from apoptosis [30, 31]